Company profile ALVO

Alvotech
alvotech was founded in 2013, with the clear mission to become a global leader in biogenerics, defined as differentiated, high-quality, cost-controlled biosimilars. we have pursued this goal by creating a fully-integrated specialty company in control of every value adding development step from cell line development to commercial manufacturing of the product. our in-house develo...pment and manufacturing platform located at four sites across europe drives timely development of a strong and differentiated portfolio, while our state-of-the-art flexible manufacturing facility, located in reykjavik iceland, ensures high quality and cost-effective production. we are passionate about what we have created and our stated purpose of transforming access to life-altering therapies for patients across the globe. we believe in focus and specialization and each of our 250 professionals share our passion and pride to be part of this mission. we are dedicated to making people's lives better by improving a Show More
Quarter analysis & expected interest

There is not enough data for Alvotech drug manufacturers to provide analysis

Correlation between past revenue and Alvotech drug manufacturers search interest

There is not enough data for Alvotech drug manufacturers to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alvotech drug manufacturers to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Alvotech biosimilar medicines to provide analysis

Correlation between past revenue and Alvotech biosimilar medicines search interest

There is not enough data for Alvotech biosimilar medicines to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alvotech biosimilar medicines to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Alvotech AVT02 Humira biosimilar to provide analysis

Correlation between past revenue and Alvotech AVT02 Humira biosimilar search interest

There is not enough data for Alvotech AVT02 Humira biosimilar to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alvotech AVT02 Humira biosimilar to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Alvotech AVT04 Stelara biosimilar to provide analysis

Correlation between past revenue and Alvotech AVT04 Stelara biosimilar search interest

There is not enough data for Alvotech AVT04 Stelara biosimilar to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alvotech AVT04 Stelara biosimilar to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Alvotech AVT06 Eylea biosimilar to provide analysis

Correlation between past revenue and Alvotech AVT06 Eylea biosimilar search interest

There is not enough data for Alvotech AVT06 Eylea biosimilar to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alvotech AVT06 Eylea biosimilar to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Alvotech AVT03 Xgeva Prolia biosimilar to provide analysis

Correlation between past revenue and Alvotech AVT03 Xgeva Prolia biosimilar search interest

There is not enough data for Alvotech AVT03 Xgeva Prolia biosimilar to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alvotech AVT03 Xgeva Prolia biosimilar to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Alvotech AVT05 Simponi biosimilar to provide analysis

Correlation between past revenue and Alvotech AVT05 Simponi biosimilar search interest

There is not enough data for Alvotech AVT05 Simponi biosimilar to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alvotech AVT05 Simponi biosimilar to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Alvotech AVT16 immunology biosimilar to provide analysis

Correlation between past revenue and Alvotech AVT16 immunology biosimilar search interest

There is not enough data for Alvotech AVT16 immunology biosimilar to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alvotech AVT16 immunology biosimilar to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Alvotech AVT23 Xolair biosimilar to provide analysis

Correlation between past revenue and Alvotech AVT23 Xolair biosimilar search interest

There is not enough data for Alvotech AVT23 Xolair biosimilar to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alvotech AVT23 Xolair biosimilar to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Alvotech AVT33 oncology biosimilar to provide analysis

Correlation between past revenue and Alvotech AVT33 oncology biosimilar search interest

There is not enough data for Alvotech AVT33 oncology biosimilar to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alvotech AVT33 oncology biosimilar to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for ALVO
Earnings date: 2024-02-28 After close
Company name: Alvotech
Sector: Professional, Scientific, and Technical Services
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-10-20T01:30:00-07:00

GlobeNewswire
Alvotech Receives FDA Approval for New SIMLANDI® Manufacturing Process That More Than Doubles Output Per Batch

2026-10-14T01:30:00-07:00

GlobeNewswire
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

2026-10-06T13:36:45-07:00

GlobeNewswire
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply

2026-09-16T12:54:50.282633711Z

Analyst Upgrades
This Union Pacific Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

2026-09-16T12:47:57.338699406Z

Analyst Upgrades
Barclays Upgrades Alvotech to Overweight, Raises Price Target to $8

2026-09-15T12:20:00-04:00

Earnings Call Transcripts
Morgan Stanley 24th Annual Global Healthcare Conference - ALVOTECH

2026-08-31T01:30:00-07:00

GlobeNewswire
Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations

2026-08-27T05:00:00-07:00

GlobeNewswire
Alvotech to present at upcoming investor conferences in September

2026-08-24T11:59:16.123324812Z

Analyst Upgrades
B of A Securities Initiates Coverage On Alvotech with Buy Rating, Announces Price Target of $7

2026-08-21T06:00:00-07:00

GlobeNewswire
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets

2026-08-20T08:00:00-04:00

Earnings Call Transcripts
Alvotech Q2 2026 Earnings Conference Call - ALVOTECH

2026-08-19T13:30:00-07:00

GlobeNewswire
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update

2026-08-14T14:05:35.589663127Z

Analyst Upgrades
Evercore ISI Group Initiates Coverage On Alvotech with Outperform Rating

2026-08-10T05:00:00-07:00

GlobeNewswire
Alvotech to Report Financial Results for H1 2026

2026-07-29T06:25:33-07:00

GlobeNewswire
Alvotech announces successful closure of FDA inspection of manufacturing facility